Alder BioPharmaceuticals (ALDR) Receives Price Target

Alder BioPharmaceuticals (ALDR) : The highest short term price target forecast on Alder BioPharmaceuticals (ALDR) is $62 and the lowest target price is $41. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $49.33 with a standard deviation of $11.15.

Alder BioPharmaceuticals (ALDR) : Zacks Investment Research ranks Alder BioPharmaceuticals (ALDR) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. The average broker rating of 4 research analysts is 1, which indicates as a Strong Buy.


Also, Equity Analysts at the Brokerage Firm, Jefferies, maintains their rating on the shares of Alder BioPharmaceuticals (NASDAQ:ALDR). Jefferies has a Buy rating on the shares. As per the latest research report, the brokerage house raises the price target to $62 per share from a prior target of $61. The rating by the firm was issued on July 27, 2016.

Alder BioPharmaceuticals (NASDAQ:ALDR): The stock opened at $32.96 on Thursday but the bulls could not build on the opening and the stock topped out at $33.23 for the day. The stock traded down to $32.05 during the day, due to lack of any buying support eventually closed down at $32.54 with a loss of -1.30% for the day. The stock had closed at $32.97 on the previous day. The total traded volume was 397,238 shares.

Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Companys pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Companys monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushings disease.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.